You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

    SBC: WellSIM Biomedical Technologies, Inc.            Topic: R

    PROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. 'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics

    SBC: Buto Corporation            Topic: NIA

    Abstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also, there is an increasing perspective at NIA that Multi-target therapy m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Ultrahigh Throughput Microscale Mass Spectrometry for Pharmaceutical Prenylation Enzyme Engineering

    SBC: Fluid Discovery Inc            Topic: 400

    Project Summary Biocatalyst can be key tools in the synthesis of natural product-based pharmaceuticals and as powerful components of the pharmaceutical chemist’s drug modification kit. For example, the aromatic prenyltransferase NphB has utility in the synthesis of common prenylated compounds or derived backbones include cannabinoids, alpha acids, beta acids, phenylpropanoids, naphterpins, and m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Enhanced pancreatic islet cell engraftment by treatment with serpin B1

    SBC: Serplus Technology, LLC            Topic: 200

    PROJECT SUMMARY The number of people with diabetes worldwide is predicted to increase from 415 million in 2015 to 642 million in 2040. The health care costs of treating diabetes accounts for 12% of the global health expenditure of which Type 1 diabetes mellitus (T1DM) constitutes 10-15% of the disease burden (IDF World Atlas 2015). T1DM is an autoimmune disease triggered by genetic and/or environm ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy

    SBC: FILTRO MEDICAL INC.            Topic: 102

    PROJECT SUMMARYDosing of chemotherapeutics is limited by systemic toxic side effects. We are developing a new class of image- guided temporarily deployable, endovascular catheter-based medical devices that selectively remove specific drugs from the blood stream to reduce systemic toxicities. The proposed ChemoFilters incorporate specialized materials that bind target drugs in situ through a variet ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. HBI-002 to Treat Parkinson’s Disease

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: 107

    PROJECT SUMMARY The goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in Parkinson’s disease (PD). A growing body of research suggests that low doses of CO - and the heme oxygenase (HO) enzymes that generate endogenous CO - protect against neuronal cell loss in PD, and epidemiologic studies have asso ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. The Nanopore-based Ion Selective Electrode Vial

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 400

    Project Summary An electrolyte panel is a blood test that measures the levels of electrolytes and carbon dioxide in your blood. Electrolytes are chemicals found naturally in the body, such as potassium, calcium, sodium, and are needed to keep the bodyandapos;s balance of fluids at the proper level and to maintain normal functions, such as heart rhythm, muscle contraction, and brain function. CO2 i ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastoma

    SBC: Algen Biotechnologies Inc            Topic: 400

    AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastoma PROJECT SUMMARY Drug discovery is a laborious, time-consuming, and expensive undertaking for biopharma. Oncology is especially difficult with new drugs in clinical trials having just 3.4% probability of success. This application addresses significant challenges of traditional drug target discover ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery

    SBC: MERCATOR MEDSYSTEMS, INC.            Topic: NHLBI

    PROJECT SUMMARY Post-thrombotic syndrome (PTS) is a chronic debilitating condition characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. It occurs within 2 years of deep vein thrombosis (DVT) treatment in 50-60% of patients with iliofemoral thrombosis and in 30-50% of all DVT patients regardless of thrombosis location (1). Even with pharmacolo ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media

    SBC: Ossium Health, Inc.            Topic: 400

    ABSTRACT:The tremendous cost of cell-based therapies manufacturing is the significant threat to the success of cell/gene therapy treatments. The cell culture medium alone can contribute to around 30-40% of the Cost of Goods (COGs). This is because, the current cell culture methods require frequent and complete media replacement in order to remove toxic metabolites from culture. This practice of co ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government